SCHEMBL190674

SCHEMBL190674

CCOC(=O)c1ccc(Cl)c(Oc2cc(Nc3nc(C)cs3)ncc2SCCC(=O)OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.41
SCD O00767 1/20 0.38
LMNA P02545 3/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSD17B10 Q99714 1/20 0.37
NPC1 O15118 5/20 0.36
RAB9A P51151 5/20 0.36
ALDH1A1 P00352 4/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CASP3 P42574 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
GAA P10253 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
TYK2 P29597 1/20 0.36
JAK3 P52333 1/20 0.36
GCK P35557 3/20 0.35
MAPT P10636 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL191677 0.85 GCK (0.45) TRPV4SCDNPC1RAB9AALDH1A1
SCHEMBL1329061 0.85 GCK (0.47) SCDLMNANPSR1HSD17B10ALDH1A1
SCHEMBL190667 0.79 SMN1; SMN2 (0.43) NPC1RAB9ASMN1; SMN2GCK
SCHEMBL191022 0.78 GCK (0.44) TRPV4SCDLMNANPSR1HSD17B10
SCHEMBL190861 0.78 GCK (0.40) NPC1RAB9AGCKHPGD
SCHEMBL1328966 0.75 GCK (0.62) SCDGCK
SCHEMBL1330089 0.75 GCK (0.56) TRPV4SCDLMNANPSR1HSD17B10
SCHEMBL14549280 0.75 GCK (0.44) TRPV4SCDLMNANPSR1HSD17B10
SCHEMBL191157 0.73 TRPV4 (0.42) TRPV4SCDLMNANPC1RAB9A
SCHEMBL190970 0.73 TRPV4 (0.40) TRPV4NPC1RAB9AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 TRPV4 4775/4885SCD 998/4885LMNA 1829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.